Non-hallucinogenic psychoplastogen; isotryptamine-derived 5-HT2A receptor partial agonist with neuroplasticity-promoting activity
A non-hallucinogenic isotryptamine psychoplastogen discovered via engineered 5-HT2A biosensor screening at UC Davis, producing rapid and sustained antidepressant-like effects through serotonin receptor-mediated structural neuroplasticity without psychedelic, dissociative, or psychotomimetic activity.
Abstract
AAZ-A-154, subsequently designated DLX-001 and assigned the international nonproprietary name zalsupindole, is a substituted isotryptamine derivative that acts as a low-potency, low-efficacy partial agonist of the serotonin 5-HT2A receptor (EC50 approximately 8,200 nM; Emax approximately 17 percent of serotonin maximum) and a moderate-efficacy partial agonist of the 5-HT2C receptor (EC50 approximately 3,300 nM; Emax approximately 70 percent), with silent antagonism at the 5-HT2B receptor and selectivity for serotonergic over dopaminergic, adrenergic, and opioid targets. The compound was first synthesized in 2019 in the laboratory of David E. Olson at the University of California, Davis, and was identified from a library screen using psychLight, a genetically encoded fluorescent biosensor constructed from the human 5-HT2A receptor with a circularly permuted green fluorescent protein inserted into the third intracellular loop [1]. PsychLight discriminated hallucinogenic from non-hallucinogenic 5-HT2A ligands on the basis of differential conformational activation signatures, and AAZ-A-154 was selected as a lead compound on the basis of its favorable ligand score, a metric that predicted non-hallucinogenic character despite retention of 5-HT2A-dependent psychoplastogenic activity.
The compound is structurally related to 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) but is an isotryptamine (the aminoalkyl side chain is attached to the indole nitrogen at position 1 rather than at position 3), a modification that repositions the compound in chemical space outside classical psychedelic tryptamines. The (R)-enantiomer is the active form; the alpha-methyl substituent on the aminoalkyl chain confers metabolic stability and enantioselective receptor engagement. The compound increased dendritic arbor complexity in cultured embryonic rat cortical neurons to a degree comparable to ketamine, and the neuroplastogenic effect was abolished by the 5-HT2 receptor antagonist ketanserin, confirming receptor dependence [1].
A comprehensive preclinical characterization published by Agrawal et al. (2025) in ACS Chemical Neuroscience demonstrated that zalsupindole promoted cortical neuritogenesis in vitro, increased dendritic spine density in the prefrontal cortex in vivo, and enhanced measures of functional plasticity to a degree comparable to or greater than ketamine, psilocybin, and N,N-dimethyltryptamine, despite lacking any of the acute cellular and behavioral characteristics of hallucinogenic or dissociative compounds [2]. Pharmacokinetic studies revealed high brain penetrance, rapid distribution, and rapid clearance. A Phase 1b study in 18 adults with major depressive disorder reported clinically meaningful reductions in Montgomery-Asberg Depression Rating Scale scores of approximately 12 points (approximately 50 percent improvement) by Day 8, with effects maintained through Day 36, and comparable efficacy between a seven-day once-daily regimen and a two-dose regimen [5]. No serious adverse events were reported across more than 120 individuals studied. Dose-dependent nausea, headache, and dizziness were the principal mild adverse events. In October 2025, the United States Food and Drug Administration cleared the Investigational New Drug application for a Phase 2, multi-site, randomized, double-blind, placebo-controlled trial in major depressive disorder featuring at-home self-administration [5]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Selective steroidal mineralocorticoid receptor antagonist with 9-alpha,11-alpha-epoxy modification conferring high receptor selectivity over androgen and progesterone receptors
A selective aldosterone antagonist derived from the spironolactone scaffold through introduction of a 9-alpha,11-alpha-epoxy group, developed across four pharmaceutical sponsors over two decades and validated in landmark heart failure and post-myocardial infarction trials as the first mineralocorticoid receptor antagonist with clinically meaningful selectivity over sex steroid hormone receptors.
Abstract
Eplerenone is a steroidal mineralocorticoid receptor (MR) antagonist and the second agent approved in this pharmacological class, reaching United States Food and Drug Administration registration in 2002 (marketed as Inspra) approximately four decades after the introduction of spironolactone, the first-generation nonselective aldosterone blocker. The compound is distinguished from spironolactone by the presence of a 9-alpha,11-alpha-epoxy bridge and a 17-alpha-carbomethoxy substituent, structural modifications that confer approximately 20- to 40-fold lower binding affinity at the mineralocorticoid receptor but approximately 500- to 800-fold greater selectivity over the androgen, progesterone, and glucocorticoid receptors. This selectivity profile eliminates the gynecomastia, breast pain, menstrual irregularity, and sexual dysfunction that limit spironolactone tolerability in chronic cardiovascular and renal indications.
The clinical evidence base for eplerenone rests on two landmark randomized controlled trials. The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), published in 2011 in the New England Journal of Medicine, enrolled 2,737 patients with chronic systolic heart failure (ejection fraction 35 percent or less) and New York Heart Association class II symptoms and demonstrated that eplerenone reduced the composite of cardiovascular death and heart failure hospitalization by 37 percent (hazard ratio 0.63; 95 percent confidence interval 0.54 to 0.74). These trials established eplerenone as a guideline-recommended therapy in heart failure with reduced ejection fraction and in post-myocardial infarction left ventricular dysfunction across all major international cardiovascular society guidelines.
Eplerenone is approved in the United States for hypertension and for heart failure following myocardial infarction with left ventricular dysfunction. The compound is also approved in the European Union, Japan, and multiple additional jurisdictions for heart failure with reduced ejection fraction. The pharmacokinetic profile is characterized by rapid oral absorption (time to maximum plasma concentration approximately 1.5 hours), absolute bioavailability of approximately 69 percent, elimination half-life of 4 to 6 hours, and predominant hepatic metabolism by cytochrome P450 3A4 (CYP3A4) with contributions from CYP3A5. The absence of clinically meaningful gynecomastia (0.7 percent versus 9 to 10 percent for spironolactone in controlled trials) is the principal tolerability advantage.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Synthetic eicosapeptide inhibitor of postsynaptic density protein 95 (PSD-95) with neuroprotective activity mediated by disruption of NMDA receptor excitotoxic signaling
A cell-permeant Tat-conjugated peptide designed to uncouple NMDA receptor activation from downstream neurotoxic signaling by inhibiting the scaffolding protein PSD-95, advanced through Phase 3 clinical trials for acute ischemic stroke neuroprotection.
Abstract
NA-1, designated nerinetide in clinical development and also known by its research name Tat-NR2B9c, is a synthetic, cell-permeant eicosapeptide composed of the 11-residue cell-membrane transduction domain of the human immunodeficiency virus type 1 (HIV-1) Tat protein fused to the nine C-terminal residues of the GluN2B (NR2B) subunit of the N-methyl-D-aspartate (NMDA) glutamate receptor. The compound was designed to inhibit the protein-protein interaction between postsynaptic density protein 95 (PSD-95) and the GluN2B subunit, thereby uncoupling NMDA receptor activation from the downstream excitotoxic signaling cascade that drives neuronal injury in ischemic stroke and related conditions, without blocking normal NMDA receptor ion channel function or calcium influx. The foundational discovery was reported by Aarts et al. in Science in 2002, demonstrating that perturbation of the NMDA receptor-PSD-95 interaction reduced excitotoxic neuronal death in vitro and focal ischemic brain damage in rats. The compound was advanced into clinical development by NoNO Inc., a Toronto-based biotechnology company founded by the originating investigator Michael Tymianski. The Phase 2 ENACT trial (Hill et al. 2012, Lancet Neurology) in 185 patients undergoing endovascular aneurysm repair demonstrated safety and a significant reduction in the number of procedure-related ischemic infarcts on diffusion-weighted magnetic resonance imaging. The Phase 3 ESCAPE-NA1 trial (Hill et al. 2020, Lancet) in 1105 patients with acute ischemic stroke undergoing endovascular thrombectomy did not meet its primary endpoint of improved 90-day modified Rankin Scale outcomes in the overall population, but a pre-specified subgroup analysis revealed a clinically meaningful 9.5 percent absolute benefit in patients who did not receive concurrent alteplase, with subsequent mechanistic work demonstrating that plasmin generated by alteplase degrades the nerinetide peptide in vivo. The Phase 3 ESCAPE-NEXT trial (2025, Lancet) in 850 patients undergoing thrombectomy without prior thrombolysis did not confirm the subgroup benefit. The Phase 2 FRONTIER trial (2025, Lancet) in 532 patients with suspected acute cerebral ischemia treated by paramedics in the prehospital setting demonstrated safety and feasibility but did not meet primary efficacy endpoints. Pharmacokinetically, nerinetide exhibits a plasma half-life of approximately 5 to 10 minutes following intravenous bolus administration, consistent with rapid peptide clearance by endogenous proteases and tissue distribution. The safety profile across all clinical trials has been favorable, with adverse event rates comparable to placebo; the only notable signal is a small excess of serious hypotension events immediately following infusion. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Hydrophilic taurine-conjugated bile acid with chemical chaperone activity and endoplasmic reticulum stress modulation
A taurine conjugate of ursodeoxycholic acid distinguished by chemical chaperone activity at the endoplasmic reticulum, cytoprotective modulation of the unfolded protein response, and broad preclinical neuroprotective and metabolic activity across neurodegenerative, hepatobiliary, retinal, and metabolic disease models.
Abstract
Tauroursodeoxycholic acid (TUDCA) is a naturally occurring hydrophilic bile acid formed by taurine conjugation of ursodeoxycholic acid (UDCA), identified in bear bile in 1902 and used in traditional Chinese medicine for centuries prior to its modern pharmacological characterization. The compound functions principally as a chemical chaperone that alleviates endoplasmic reticulum (ER) stress by stabilizing the unfolded protein response (UPR) through modulation of the three canonical ER stress sensor pathways: PERK/eIF2alpha/ATF4, IRE1alpha/XBP1, and ATF6. Beyond ER stress modulation, TUDCA exerts potent anti-apoptotic activity through prevention of Bax translocation to mitochondrial membranes, inhibition of cytochrome c release, and activation of the PI3K/Akt survival pathway. The compound stabilizes mitochondrial membrane potential, reduces reactive oxygen species production, suppresses NF-kappaB-mediated proinflammatory cytokine release, and activates the nuclear receptor FXR and the membrane receptor TGR5. TUDCA crosses the blood-brain barrier and has demonstrated neuroprotective activity in preclinical models of Alzheimer’s disease (APP/PS1 transgenic mice, reducing amyloid-beta deposition and rescuing spatial memory), Parkinson’s disease (MPTP model, preventing dopaminergic neuronal loss), Huntington’s disease (3-nitropropionic acid model, preserving striatal mitochondria), amyotrophic lateral sclerosis (SOD1 transgenic mice), retinal degeneration (multiple retinitis pigmentosa models), and ischemic stroke (reducing infarct volume by approximately 50 percent). A separate European Phase III trial (TUDCA-ALS) of TUDCA monotherapy in 337 ALS patients similarly failed to demonstrate efficacy at 18 months. The compound has been licensed for the treatment of cholestatic liver disease and cholesterol gallstones in several European and Asian jurisdictions since 1991 and maintains a favorable safety profile, with the principal adverse events being mild gastrointestinal effects (diarrhea in approximately 14 percent, abdominal pain in approximately 6 percent). This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Cycloartane-type triterpenoid saponin glycoside derived from Astragalus membranaceus with pleiotropic anti-inflammatory, antioxidant, and cytoprotective activity
A cycloartane triterpenoid saponin isolated from Astragalus membranaceus (Huangqi) that modulates NF-kB, PI3K/Akt, and Nrf2/HO-1 signaling to produce cardioprotective, neuroprotective, hepatoprotective, and immunomodulatory effects across a broad preclinical evidence base.
Abstract
Astragaloside IV (AS-IV) is a cycloartane-type triterpenoid saponin glycoside and the principal pharmacologically active saponin constituent of Astragalus membranaceus (Huangqi), a botanical drug with over two thousand years of documented use in traditional Chinese medicine for tonification of qi, immune support, and cardiovascular health. The compound, bearing the molecular formula C41H68O14 and a molecular weight of 784.97, consists of a cycloartane aglycone skeleton conjugated to beta-D-glucose and beta-D-xylose sugar moieties. Astragaloside IV has emerged over the past two decades as one of the most extensively investigated natural product saponins in modern pharmacology, with a research literature now spanning cardioprotection, neuroprotection, hepatoprotection, nephroprotection, pulmonary fibrosis attenuation, anti-tumor activity, metabolic syndrome modulation, and telomerase activation through its principal gut-microbial metabolite cycloastragenol.
The molecular pharmacology of astragaloside IV is characterized by multi-target activity across several canonical signaling cascades. The compound inhibits the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway through suppression of IkB phosphorylation and reduction of nuclear translocation, producing dose-dependent reductions in tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 in activated macrophages and in lipopolysaccharide-challenged animal models. Concurrently, astragaloside IV activates the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant response element pathway, upregulating superoxide dismutase, glutathione peroxidase, and catalase expression. The compound modulates the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling axis with context-dependent activation (cardioprotection, neuroprotection) or inhibition (anti-tumor applications), and suppresses the transforming growth factor beta 1 (TGF-beta1)/Smad pathway to attenuate fibrotic remodeling in lung, liver, and kidney tissue. Additional characterized targets include Toll-like receptor 4 (TLR4), the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor gamma (PPARgamma), and glycogen synthase kinase 3 beta (GSK3beta).
Pharmacokinetics present the principal translational challenge for astragaloside IV. Oral bioavailability in rats is approximately 2.2 to 3.7 percent, and in beagle dogs approximately 7.4 percent, reflecting high molecular weight, poor aqueous solubility, limited intestinal membrane permeability, and predominantly paracellular absorption. The compound undergoes extensive biotransformation by intestinal microflora (principally Bifidobacteria and Lactobacillus species) through sequential deglycosylation to produce cycloastragenol, the aglycone metabolite that is substantially more bioavailable and that mediates telomerase activation through upregulation of human telomerase reverse transcriptase (hTERT) gene expression via the mitogen-activated protein kinase (MAPK) pathway. Plasma elimination half-life in rats after oral administration is approximately 3.8 hours, with highest tissue concentrations in lung and liver.
The preclinical evidence base is extensive and spans multiple organ systems. In focal cerebral ischemia models, the compound reduces infarct volume and neurological deficit scores through Nrf2/HO-1 activation and NF-kB suppression. In carbon tetrachloride and high-fat-diet hepatotoxicity models, astragaloside IV preserves hepatocyte integrity through antioxidant and anti-inflammatory mechanisms. In diabetic nephropathy models, the compound attenuates glomerular basement membrane thickening and reduces proteinuria. In bleomycin-induced pulmonary fibrosis models, astragaloside IV suppresses collagen deposition through TGF-beta1/Smad pathway inhibition.
Clinical evidence in humans remains limited. Astragalus membranaceus extract preparations containing astragaloside IV as a standardized marker compound are registered in the Chinese Pharmacopoeia and are widely used in clinical practice in China, Japan, and the Republic of Korea for cardiovascular, hepatic, and immune-support indications. The telomerase-activating metabolite cycloastragenol is the active principle of the commercial nutraceutical TA-65, which has produced positive telomere-lengthening results in randomized controlled trials in middle-aged and older adults.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Non-benzodiazepine benzoxazine anxiolytic with dual GABAA receptor positive allosteric modulation and TSPO-mediated neurosteroidogenesis
A non-benzodiazepine benzoxazine derivative developed by Hoechst AG and marketed as Stresam, distinguished from classical benzodiazepine anxiolytics by a dual mechanism encompassing direct positive allosteric modulation of beta2/beta3-containing GABAA receptors and stimulation of endogenous neurosteroid biosynthesis through the 18 kDa translocator protein (TSPO), conferring anxiolytic, anticonvulsant, and neuroprotective activity without the sedation, amnesia, tolerance, and dependence liabilities of the benzodiazepine class.
Abstract
Etifoxine (6-chloro-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine) is a non-benzodiazepine anxiolytic of the benzoxazine structural class, first synthesized by Hoechst AG in 1966 and introduced for clinical use in France in 1979 under the trade name Stresam. The compound is marketed in approximately 40 countries for the treatment of anxiety disorders, principally adjustment disorders with anxiety, but has not been approved by the United States Food and Drug Administration or by the European Medicines Agency for centralized marketing authorization across the European Union. Etifoxine is pharmacologically distinguished from both the benzodiazepine class and from other non-benzodiazepine anxiolytics (buspirone, hydroxyzine) by a dual mechanism of action at the GABAergic system. The first mechanism is direct positive allosteric modulation of the GABAA receptor through binding at the beta subunit, with preferential potentiation of receptors containing beta2 or beta3 subunits, at a site distinct from the benzodiazepine binding site located at the alpha/gamma interface. The second mechanism is binding to the 18 kDa translocator protein (TSPO, formerly the peripheral benzodiazepine receptor) on the outer mitochondrial membrane, which stimulates the translocation of cholesterol into the mitochondrial matrix and the subsequent biosynthesis of endogenous neurosteroids, principally pregnenolone, progesterone, 5-alpha-dihydroprogesterone, and allopregnanolone. Allopregnanolone is itself a potent positive allosteric modulator of the GABAA receptor at the neurosteroid binding site (distinct from both the benzodiazepine and the etifoxine direct binding sites), producing a convergent, temporally extended potentiation of GABAergic inhibitory neurotransmission. This dual mechanism produces anxiolytic efficacy comparable to benzodiazepines in clinical trials of adjustment disorder with anxiety, with significantly reduced incidence of sedation, psychomotor impairment, amnesia, rebound anxiety on withdrawal, and physical dependence. Pharmacokinetics are characterized by rapid oral absorption, high bioavailability (approximately 90 percent), hepatic metabolism to an active metabolite (diethyl-etifoxine) with a half-life of approximately 20 hours, and predominant renal excretion. The clinical evidence base includes multiple randomized controlled trials comparing etifoxine to lorazepam, alprazolam, and placebo in adjustment disorder with anxiety, with the AMETIS study (a three-arm trial versus lorazepam and placebo) producing a notable negative result in which neither active arm separated from placebo. The compound has an established clinical safety profile over more than 40 years of marketed use, with rare but serious adverse events including severe cutaneous reactions (drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, erythema multiforme) and hepatotoxicity (acute cytolytic hepatitis), which prompted a 2021 European Medicines Agency Article 31 referral concluded in January 2022 with continued marketing authorization subject to contraindication in patients with prior severe dermatological or hepatic reactions. Beyond the anxiolytic indication, etifoxine has generated a substantial preclinical research literature in neuroprotection following peripheral nerve injury, traumatic brain injury, experimental autoimmune encephalomyelitis (a model of multiple sclerosis), and neuropathic pain, with the neuroprotective activity attributed to TSPO-mediated neurosteroidogenesis and downstream anti-inflammatory and neurotrophic effects. A deuterated analog, GRX-917 (GABA Therapeutics, a subsidiary of atai Life Sciences), has completed Phase 1 clinical trials with improved pharmacokinetic properties and is in development for anxiety and related disorders. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
A highly beta-1 selective adrenergic receptor antagonist distinguished from all other marketed beta-blockers by endothelial nitric oxide-dependent vasodilation mediated through beta-3 adrenergic receptor agonism and GRK/beta-arrestin biased signaling, conferring hemodynamic, metabolic, and tolerability advantages in hypertension and heart failure.
Abstract
Nebivolol is a third-generation beta-adrenergic receptor antagonist with the highest beta-1 selectivity among clinically available beta-blockers and a unique vasodilatory mechanism mediated by endothelial nitric oxide (NO) release. The compound was patented by Janssen Pharmaceutica in 1983, entered clinical use in Europe in 1997, and received United States Food and Drug Administration approval in December 2007 for the treatment of hypertension, marketed as Bystolic by Forest Laboratories (now Allergan/AbbVie). Nebivolol is a racemic mixture of equal proportions of d-nebivolol (SRRR configuration) and l-nebivolol (RSSS configuration), each containing four stereocenters within a bis-chromanol scaffold linked by an aminoethanol bridge. The d-enantiomer carries the beta-1 adrenergic antagonist activity, while the l-enantiomer predominantly mediates nitric oxide release through beta-3 adrenergic receptor agonism and activation of endothelial nitric oxide synthase (eNOS) via serine-1177 phosphorylation. This dual mechanism produces a hemodynamic profile that combines heart rate reduction and negative inotropy (classical beta-blockade) with peripheral vasodilation and reduced systemic vascular resistance (NO-mediated), distinguishing nebivolol from older beta-blockers that increase or fail to reduce peripheral resistance.
The pharmacokinetic profile is dominated by extensive hepatic metabolism through cytochrome P450 2D6 (CYP2D6), producing a striking polymorphic phenotype: oral bioavailability is approximately 12 percent in extensive metabolizers and rises to approximately 96 percent in poor metabolizers. The plasma elimination half-life of d-nebivolol is approximately 12 hours in extensive metabolizers and approximately 19 hours in poor metabolizers. Steady-state plasma concentrations in poor metabolizers are 10- to 15-fold higher than in extensive metabolizers at equivalent doses. The CYP2D6 dependence has direct clinical implications for dose adjustment, drug-drug interactions with CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine), and inter-individual variability in blood pressure response.
The principal clinical evidence base comprises the SENIORS trial (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure), which randomized 2128 elderly patients (age 70 years or older) with symptomatic heart failure to nebivolol or placebo and demonstrated a significant reduction in the composite primary endpoint of all-cause mortality or cardiovascular hospital admission (hazard ratio 0.86, 95 percent confidence interval 0.74 to 0.99, P = 0.039). Multiple randomized controlled trials in hypertension have demonstrated blood pressure reductions comparable to or exceeding those of other beta-blockers, with superior tolerability including significantly lower rates of fatigue, sexual dysfunction, and metabolic derangement (glucose and lipid abnormalities). Preclinical evidence demonstrates cardioprotective, antioxidant, and anti-inflammatory properties mediated through beta-3 receptor stimulation, NLRP3 inflammasome suppression, and mitochondrial biogenesis enhancement.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Senolytic Bcl-xL inhibitor (phosphate prodrug); small-molecule inducer of apoptosis in senescent retinal vascular endothelial cells
A first-in-class senolytic Bcl-xL inhibitor developed by Unity Biotechnology as an intravitreal therapy for diabetic macular edema and age-related macular degeneration, distinguished from conventional anti-VEGF agents by its mechanism of selective elimination of senescent retinal vascular cells and its potential for durable, disease-modifying efficacy from infrequent dosing.
Abstract
UBX1325 (foselutoclax) is a soluble phosphate prodrug that is cleaved rapidly in ocular tissues by ubiquitous phosphatases to yield the active parent molecule UBX0601, a potent inhibitor of the B-cell lymphoma-extra large (Bcl-xL) anti-apoptotic protein and related Bcl-2 family members. The compound was developed by Unity Biotechnology as the first senolytic therapeutic candidate designed for intravitreal administration in ophthalmologic indications, principally diabetic macular edema (DME), diabetic retinopathy (DR), and neovascular (wet) age-related macular degeneration (AMD). The senolytic mechanism is fundamentally distinct from the anti-vascular endothelial growth factor (anti-VEGF) agents that constitute the current standard of care for these conditions: rather than neutralizing a single cytokine to reduce vascular permeability, UBX1325 selectively induces apoptosis in senescent retinal vascular endothelial cells that have accumulated in areas of disease activity, thereby removing a persistent source of pro-inflammatory and pro-permeability signaling and potentially modifying the underlying disease process rather than managing its downstream consequences.
The compound originated from a 2016 strategic licensing arrangement between Unity Biotechnology and Ascentage Pharma, under which Unity screened Ascentage’s Bcl-2 family compound library for candidates with senolytic activity against age-related disease targets. The selected molecule, BM-962, was optimized as a phosphate prodrug (UBX1325/foselutoclax) to improve aqueous solubility for ophthalmic formulation. Preclinical studies demonstrated that intravitreal administration of UBX1325 in oxygen-induced retinopathy and streptozotocin-induced diabetic retinopathy mouse models selectively eliminated senescent cells from diseased retinal vasculature while sparing healthy tissue, reduced retinal vascular permeability, and improved retinal function as measured by electroretinography. These results, published in Nature Medicine in 2024, represent the first clinical demonstration of senolytic therapy in ophthalmology. The Phase 2 ENVISION trial (NCT05275205) in wet AMD did not meet its primary non-inferiority endpoint versus aflibercept at 24 weeks, though 40 percent of UBX1325-treated patients required no anti-VEGF rescue through 48 weeks. The Phase 2b ASPIRE trial (NCT06011798) evaluated repeat dosing of UBX1325 every 8 weeks versus aflibercept every 8 weeks in 52 DME patients; at 36 weeks, UBX1325 produced mean gains of 5.5 ETDRS letters, achieving non-inferiority to aflibercept at most time points except the pre-specified primary endpoint (average of weeks 20 and 24), with superior performance in a pre-specified subgroup of patients with baseline central subfield thickness below 400 microns.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Vicia faba-derived dopaminergic bioproduct with natural L-DOPA donor activity and neuroprotective properties
A standardized biopharmaceutical extract (E-PodoFavalin-15999) obtained by non-denaturing biotechnological procedures from structural components of Vicia faba L., functioning as a potent dopaminergic enhancer, natural L-DOPA donor, and neuroprotective agent for the prevention and treatment of Parkinsonian disorders, with genotype-dependent catecholaminergic and hormonal modulation.
Abstract
Atremorine (E-PodoFavalin-15999) is a novel biopharmaceutical product obtained by non-denaturing biotechnological processing of structural components of Vicia faba L. (the broad bean or fava bean), developed at the EuroEspes Biomedical Research Center (now International Center of Neuroscience and Genomic Medicine, Bergondo, A Coruna, Spain) under the direction of Ramon Cacabelos for the prevention and treatment of Parkinson’s disease (PD) and related dopamine-dependent disorders. Unlike synthetic levodopa (L-DOPA) formulations, Atremorine is a complex bioproduct containing a standardized concentration of approximately 25 mg of natural L-DOPA per gram of product, together with vegetal proteins, unsaturated fatty acids, minerals, vitamins, vegetal fiber, starch, carotenoid pigments, and phytosterols, all of which are proposed to contribute synergistically to its pharmacological activity and to confer neuroprotective properties absent from purified synthetic L-DOPA.
Preclinical studies in cell culture (human neuroblastoma SH-SY5Y cells, hippocampal slices under oxygen-glucose deprivation, striatal slices under 6-hydroxydopamine-induced neurotoxicity) and in animal models (MPTP-induced parkinsonism in mice) have demonstrated that Atremorine protects dopaminergic neurons against neurotoxic insult, inhibits microglial activation, and improves motor function [1, 2, 3]. In drug-free PD patients, plasma dopamine levels increase from approximately 12 pg/mL to approximately 6,463 pg/mL; in patients receiving conventional antiparkinsonian therapy, dopamine levels increase from approximately 1,322 pg/mL to approximately 16,029 pg/mL, indicating substantial potentiation of conventional dopaminergic pharmacotherapy [5, 6]. The dopamine response is accompanied by significant changes in circulating catecholamines (adrenaline, noradrenaline) and in dopamine-regulated hormones (reductions in prolactin, cortisol, and growth hormone), with no significant effect on serotonin or histamine levels [4].
The variability in the Atremorine-induced dopamine response is highly attributable to pharmacogenetic factors. Polymorphic variants in pathogenic genes (notably APOE), metabolic genes (CYP2D6, CYP2C9, CYP2C19, CYP3A4/5), and neurotransmitter transporter genes (SLC6A3/DAT, SLC6A2/NET, SLC6A4/SERT) exert genotype-dependent effects on the magnitude of the dopamine response [5, 7, 8]. APOE-3 carriers are the best responders and APOE-4 carriers are the worst; CYP2D6 normal metabolizers respond most strongly and CYP2D6 poor metabolizers respond least [5, 7]. Atremorine also exerts epigenetic activity, increasing global DNA methylation in both transgenic Alzheimer’s disease mice (3xTg model) and in PD patients, with upregulation of the de novo DNA methyltransferase DNMT3a [9]. The coadministration of Atremorine with conventional antiparkinsonian drugs allows dose reduction of the conventional agents by 25 to 50 percent, with enhancement of clinical benefits and reduction of short- and long-term adverse drug reactions [5, 6]. The compound is covered by European Patent EP3225245A1 and related filings. It is not approved by any major regulatory authority as a pharmaceutical; it is classified and distributed as a bioproduct or nutraceutical. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
A 2-azetidinone cholesterol absorption inhibitor developed at the Schering-Plough Research Institute, first-in-class for selective blockade of Niemann-Pick C1-Like 1 mediated intestinal sterol uptake, with landmark cardiovascular outcomes evidence from the IMPROVE-IT trial and broad clinical positioning as add-on therapy to statins.
Abstract
Ezetimibe is a selective cholesterol absorption inhibitor and the founding member of a pharmacological class that targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein at the brush border membrane of small intestinal enterocytes and on the canalicular membrane of hepatocytes. Developed at the Schering-Plough Research Institute through a medicinal chemistry program that originated in acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor optimization, the compound was identified as SCH 58235 and advanced to regulatory approval by the United States Food and Drug Administration in October 2002 for the treatment of primary hypercholesterolemia, homozygous familial hypercholesterolemia, homozygous sitosterolemia, and mixed hyperlipidemia. The molecular mechanism involves direct binding to NPC1L1, a polytopic transmembrane protein with sterol-sensing domains homologous to the Niemann-Pick type C1 protein (NPC1), blocking the clathrin/AP2-mediated endocytosis of the NPC1L1-cholesterol complex and thereby preventing cholesterol translocation from the intestinal lumen into the enterocyte cytoplasm.
The pharmacokinetic profile is dominated by rapid absorption followed by extensive first-pass glucuronidation to the pharmacologically active ezetimibe-glucuronide conjugate, which constitutes 80 to 90 percent of circulating drug. Both ezetimibe and its glucuronide undergo enterohepatic recirculation, producing a prolonged effective half-life of approximately 22 hours that supports once-daily dosing. Metabolism is mediated principally by uridine 5′-diphosphate-glucuronosyltransferase (UGT) isoenzymes 1A1, 1A3, and 2B15, with minimal cytochrome P450 involvement, conferring a favorable drug-drug interaction profile relative to the statin class. Approximately 78 percent of the administered dose is excreted in feces, predominantly as parent ezetimibe, with the remainder recovered in urine as the glucuronide conjugate.
The clinical evidence base for ezetimibe is anchored by two landmark cardiovascular outcomes trials. The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), published in 2015, randomized 18,144 patients with recent acute coronary syndrome to simvastatin plus ezetimibe versus simvastatin plus placebo and demonstrated a statistically significant 6.4 percent relative reduction in the primary composite cardiovascular endpoint (hazard ratio 0.936, p = 0.016) at a median follow-up of six years, establishing ezetimibe as the first non-statin lipid-lowering agent to demonstrate incremental cardiovascular benefit when added to statin therapy [1]. The SHARP trial (Study of Heart and Renal Protection) randomized approximately 9,270 patients with chronic kidney disease to simvastatin plus ezetimibe versus placebo and demonstrated significant reduction in major atherosclerotic events [2]. These trials collectively validated the LDL-C hypothesis beyond the statin class and positioned ezetimibe as a standard component of guideline-directed lipid management.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.